Asano Y, et al. - Researchers intended to ascertain how the expressions of the immune checkpoint proteins affected responses to neo-adjuvant chemotherapy (NAC) in breast cancer. During this study, estrogen receptor, progesteron receptor, human epidermal growth factor receptor 2, Ki67, PD-L1, PDL-2 and PD-1 status were evaluated via immunohistochemistry. Findings disclosed that the patients with high programmed cell death (PD)-1 and programmed cell death-ligand (PD-L) 1 expressions presented with a considerably higher rate of triple-negative breast cancer (TNBC). It was inferred that PD-1 and PD-L1 expressions could serve as beneficial biomarkers for speculating the treatment responses to NAC in breast cancer. The PD-L1 expression was possibly found to be useful as biomarkers for more effective chemotherapy in TNBC.